Details of the Drug Reposition

General Information of This Drug (ID: DMRBMAU)

Drug Name
Mycophenolic acid   DMRBMAU
Synonyms
Micofenolico acido; Micofenolico acido [Spanish]; Mycophenoic acid; Mycophenolate; Mycophenolsaeure; Myfortic; mycophenolic acid; Acide mycophenolique; Acido micofenolico; Acido micofenolico [INN-Spanish]; Acidum mycophenolicum; Lilly-68618; Ly 68618; Melbex; (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid; 24280-93-1; 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid; CCRIS 5565; NSC 129185; NSC-129185; UNII-HU9DX48N0T
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
14 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Leukemia DISNAKFL N.A. Approved [1]
Testicular lymphoma DISC2M2N N.A. Approved [2]
Splenic marginal zone lymphoma DISCGTZY N.A. Approved [2]
Small intestine lymphoma DISDOS6S N.A. Approved [2]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified DIS5OHQF N.A. Approved [2]
MALT lymphoma DIS1AVVE N.A. Approved [2]
Hepatosplenic T-cell lymphoma DIS7KMY9 N.A. Approved [2]
Myeloproliferative neoplasm DIS5KAPA 2A20 Approved [3]
Recurrent adult burkitt lymphoma DIS6V60A 2A85.6 Approved [2]
Large granular lymphocytic leukemia DISHOPPI 2A90.1 Approved [2]
Myeloid leukaemia DISMN944 2B33.1 Approved [4]
Lupus nephritis DISCVGPZ 4A40.0Y Approved [5]
Crohn disease DIS2C5Q8 DD70 Approved [6]
Interstitial cystitis DIS7CAJA GC00.3 Approved [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 Indications(s)
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Post-transplant lymphoproliferative disorder DISTS43D 2B32 Discontinued in Phase 2 [8]
------------------------------------------------------------------------------------
3 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Classic Hodgkin lymphoma DISV1LU6 N.A. Investigative [9]
Middle East Respiratory Syndrome (MERS) DIS5VPYU 1D64 Investigative [10]
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Investigative [11]
------------------------------------------------------------------------------------

References

1 New conjugates of mycophenolic acid and their antiproliferative activity. J Asian Nat Prod Res. 2016 Nov;18(11):1057-62.
2 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
3 Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 Jul;25(7):1407-1415.
4 Mycophenolic Acid overcomes imatinib and nilotinib resistance of chronic myeloid leukemia cells by apoptosis or a senescent-like cell cycle arrest. Leuk Res Treatment. 2012;2012:861301.
5 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-723.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
7 Early termination of a trial of mycophenolate mofetil for treatment of interstitial cystitis/painful bladder syndrome: lessons learned. J Urol. 2011 Mar;185(3):901-6.
8 Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers
9 Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map database. Pathol Res Pract. 2018 Nov;214(11):1854-1867.
10 SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016 Aug;14(8):523-34.
11 Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020 Mar 27;14:1022.